Literature DB >> 15106299

Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission.

R Bruce Aylward1, Stephen L Cochi.   

Abstract

With the interruption of wild poliovirus transmission globally, the need for new policies to deal with the post-certification era will rapidly arise. New policies will be required in four areas: detection and notification of circulating polioviruses; biocontainment of wild, vaccine-derived and attenuated strains of poliovirus; vaccine stockpiles and response mechanisms; and routine immunization against polioviruses. A common understanding of the potential risks of paralytic poliomyelitis in the post-certification period is essential to the development of these policies. Since 2000, there has been increasing international consensus that the risks of paralytic poliomyelitis in the post-certification era fall into two categories: those due to the continued use of the oral poliovirus vaccine (OPV) and those due to future improper handling of wild polioviruses. The specific risks within both categories have now been defined, and an understanding of the frequency and potential burden of disease associated with each is rapidly improving. This knowledge and clarity have provided a framework that is already proving valuable for identifying research priorities and discussing potential policy options with national authorities. However, this framework must be regarded as a dynamic tool, requiring regular updating as additional information on these risks becomes available through further scientific research, programmatic work, and policy decisions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15106299      PMCID: PMC2585888     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  4 in total

1.  Can we capitalize on the virtues of vaccines? Insights from the polio eradication initiative.

Authors:  R Bruce Aylward; David L Heymann
Journal:  Am J Public Health       Date:  2005-05       Impact factor: 9.308

2.  Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient.

Authors:  Chen-Fu Yang; Hour-Young Chen; Jaume Jorba; Hui-Chih Sun; Su-Ju Yang; Hsiang-Chi Lee; Yhu-Chering Huang; Tzou-Yien Lin; Pei-Jer Chen; Hiroyuki Shimizu; Yorihiro Nishimura; Andi Utama; Mark Pallansch; Tatsuo Miyamura; Olen Kew; Jyh-Yuan Yang
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.

Authors:  R J Duintjer Tebbens; K M Thompson
Journal:  Epidemiol Infect       Date:  2016-10-20       Impact factor: 2.451

4.  Towards an effective poliovirus laboratory containment strategy in Nigeria.

Authors:  Johnson Muluh Ticha; Kolawole Olatunji Matthew; Abdullahi Walla Hamisu; Braka Fiona; Pascal Mkanda; Peter Nsubuga; Eberto Tesfaye; Kehinde Craig; Etsano Andrew; Obi Emelife; Faisal Shuaib; Akinkugbe Folasade; Johnson Adeniji; Usman Adamu; Mohammed Dallatu; Geoffrey Oyeyinka; Holly Brown; Nwakasik Nnamah; Joseph Okwori; Chukwuike Chinedu; Ibikunle Anibijuwon; Adewumi Olubusuyi; Donbraye Emmanuel; Murtala Bagana; Marycelin Baba; Gumede Nicksy; Richard Banda; Sisay G Tegegne; Ajiboye Oyetunji; Ousmane Diop; O Tomori; Rui G Vaz
Journal:  BMC Public Health       Date:  2018-12-13       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.